[1] Nickoloff BJ, Foreman KE. Etiology and pathogenesis of Kaposi's sarcoma. Recent Results Cancer Res, 2002, 160:332-342. [2] Dezube BJ. The role of human immunodeficiency virus-I in the pathogenesis of acquired immunodeficiency syndrome-related Kaposi's sarcoma: the importance of an inflammatory and angiogenic milieu. Semin Oncol, 2000, 27:420-423. [3] Simonart T, Hermans P, Schandene L, et al. Phenotypic characteristics of Kaposi's sarcoma tumour cells derived from patch-,plaque- and nodular-stage lesions: analysis of cell cultures isolated from AIDS and non-AIDS patients and review of the literature. Br J Dermatol, 2000, 143:557-563. [4] Ensoli B, Barillari G, Salahuddin SZ, et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature, 1990, 345:84-86. [5] Puig L, Fernandez-Figueras MT, Penin RM, et al. Differential expression of c-Met in Kaposi's sarc oma according to progression stage and HIV infection status. J Cutan Pathol, 1999, 26:227-231. [6] Polverini PJ, Nickoloff BJ. Role of scatter factor and the c-met protooncogene in the pathogenesis of AIDS-associated Kaposi's sarcoma. Adv Cancer Res, 1995, 66:235-253. [7] Maier JA, Mariotti M, Albini A, et al. Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. Int J Cancer, 1996,65:168-172. [8] Fernandez-Figueras MT, Puig L, Penin RM, et al. Decreased immunoreactivity for cell-cycle regulator p27(Kip1) in Kaposi's sarcoma correlates with higher stage and extracutaneous involvement.J Pathol, 2000, 191:387-393. |